EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The impact of rifampin drug interactions on tuberculosis preventive treatment completion and safety

F Fregonese, J White, R K Lim, N Bedingfield, V J Cook, F Gafar, D Gibson, D Menzies, D Fisher

The International Journal of Tuberculosis and Lung Disease · 27.03.2026 · 30 (4) · 167-173

DOI: 10.5588/ijtld.25.0345 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, erschienen am 27.03.2026. Verfasst von F Fregonese und 8 weiteren Autor:innen. Beteiligte Einrichtung: McGill International TB Centre, McGill University, Montreal, QC, Canada. Hauptthemen laut MEDLINE: Rifampin, Tuberculosis, Antitubercular Agents, Antibiotics, Antitubercular. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND

Rifamycin TB preventive treatment (TPT) is critical to TB elimination. However, clinicians may be reluctant to recommend it over concerns related to drug–drug interactions (DDI). In this secondary analysis of data from the 2R 2 randomised clinical trial (comparing standard dose rifampin to high-dose rifampin for TPT), we investigate if participants taking medications with potential rifampin DDI had similar TPT completion, safety, and follow-up visits compared to those without.





METHODS

Data on concomitant medications, adverse events, treatment completion, and follow-up visits were compared between participants with and without potential rifampin DDI. Analyses were conducted with R, reporting risk difference (RD) using g-computation with logistic regression.





RESULTS

282 of 1,368 participants (21%) were taking essential medications with potential rifampin DDI. There was no RD in TPT completion (RD 0.04 [95% confidence interval (CI): −0.02; 0.09]) or adverse events (RD 0.02 [95% CI: −0.01; 0.06]) between participants with and without these medications. Individuals talking medications with potential DDI had a higher percentage of two or more unscheduled visits (12%) compared to those not taking them (5%) ( P = 0.0001).





CONCLUSION

In participants taking medications with potential rifampin DDI, rifampin TPT can be used safely without impacting completion rates. However, additional follow-up visits should be anticipated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinTuberculosisAntitubercular AgentsAntibiotics, AntitubercularHumansDrug InteractionsFemaleMaleLogistic ModelsAdultTreatment Outcome

Substanzen

RifampinAntitubercular AgentsAntibiotics, Antitubercular

Autor:innen und Institutionen

  • McGill International TB Centre, McGill University, Montreal, QC, Canada.
  • Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada.
  • Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada;, Division of Respiratory Medicine, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
  • Calgary Tuberculosis Services, Alberta Health Services, Calgary, AB, Canada;, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University…
  • Department of Medicine, University of British Columbia, Vancouver, BC, Canada;, Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada.
  • McGill International TB Centre, McGill University, Montreal, QC, Canada;, Respiratory Epidemiology and Clinical Research Unit, Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Hea…

Zitieren

APA

Fregonese, F., White, J., Lim, R. K., Bedingfield, N., Cook, V. J., Gafar, F., Gibson, D., Menzies, D., & Fisher, D. (2026). The impact of rifampin drug interactions on tuberculosis preventive treatment completion and safety. The International Journal of Tuberculosis and Lung Disease, 30(4), 167-173. https://doi.org/10.5588/ijtld.25.0345

Vancouver

Fregonese F, White J, Lim RK, Bedingfield N, Cook VJ, Gafar F, et al. The impact of rifampin drug interactions on tuberculosis preventive treatment completion and safety. The International Journal of Tuberculosis and Lung Disease. 2026;30(4):167-173. doi:10.5588/ijtld.25.0345

BibTeX
@article{Fregonese2026,
  author = {Fregonese, F and White, J and Lim, R K and Bedingfield, N and Cook, V J and Gafar, F and Gibson, D and Menzies, D and Fisher, D},
  title = {The impact of rifampin drug interactions on tuberculosis preventive treatment completion and safety},
  journal = {The International Journal of Tuberculosis and Lung Disease},
  year = {2026},
  volume = {30},
  number = {4},
  pages = {167--173},
  doi = {10.5588/ijtld.25.0345}
}
Kostenlos starten →